Dr. Reddy’s Laboratories announced its Q2 and H1 FY26 results, showcasing revenue growth. Q2 FY26 revenue reached ₹88.05 billion, up 9.8% YoY, while H1 FY26 revenue hit ₹173.5 billion, a 10.6% YoY increase. The company’s performance was driven by momentum in branded markets and nicotine replacement therapy. Focus remains on core business strength, pipeline advancement and productivity.
Financial Highlights for Q2 FY26
Dr. Reddy’s Laboratories (DRL) reported the following key figures for the second quarter of fiscal year 2026:
- Revenue: ₹88.05 billion (Up 9.8% YoY)
- Gross Margin: 54.7%
- SG&A Expenses: ₹26.44 billion (Up 15% YoY)
- R&D Expenses: ₹6.20 billion (7.0% of Revenues)
- EBITDA: ₹23.51 billion
- Profit Before Tax: ₹18.35 billion (Down 4% YoY)
- Profit After Tax: ₹14.37 billion (Up 14% YoY)
Financial Highlights for H1 FY26
Key financial achievements for the first half of FY26 include:
- Revenue: ₹173.50 billion (Up 10.6% YoY)
- Gross Margin: 55.8%
- SG&A Expenses: ₹52.08 billion (Up 14% YoY)
- R&D Expenses: ₹12.45 billion (7.2% of Revenues)
- EBITDA: ₹46.29 billion
- Profit Before Tax: ₹37.40 billion (Down 2% YoY)
- Profit After Tax: ₹28.55 billion (Up 8% YoY)
Segment Performance
A breakdown of revenue by segment for Q2 FY26:
- Global Generics: ₹78.50 billion (Up 10% YoY)
- Pharmaceutical Services and Active Ingredients (PSAI): ₹9.45 billion (Up 12% YoY)
Key Business Highlights
Significant developments during the quarter include:
- Acquisition of the STUGERON portfolio.
- Launch of Linaclotide in India under the brand name ‘Colozo’.
- Partnership with Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI to enhance access to Lenacapavir.
- Subject Expert Committee recommendation for Semaglutide injection in India.
Source: BSE